IO Biotech enrols 380 patients with advanced melanoma in phase 3 trial
The trial is evaluating an investigational cancer vaccine in combination with Keytruda
Read More
Tag: pembrolizumab
MSD’s pembrolizumab therapy gets NICE approval
1,500 people set to receive new skin cancer treatment that reduces the risk of it returning
Read More
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta
NICE says the combination’s cost-effectiveness estimate is higher than what is considered acceptable for NHS use
Read More
MSD’s Keytruda bags approval for new skin cancer indication
In trials Keytruda showed ‘meaningful efficacy’ with an objective response rate of 34%
Read More
MSD’s Keytruda misses advanced bladder cancer goal
The drug did not significantly improve overall survival or progression free survival in the first-line setting
Read More
MSD’s Keytruda doubles PFS in bowel cancer subset
The ‘game-changing’ results will likely result in a paradigm shift in current clinical practice, researchers said
Read More
Keytruda misses key lung cancer survival endpoint
The drug significantly improved progression-free survival, but missed its overall survival endpoint.
Read More
EMA positive opinion granted for Keytruda combo
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorisation.
Read More
LifeArc receives $1.2b in Keytruda royalties
In 2016, LifeArc sold a small proportion of its Keytruda royalty interest for $150 million to a private equity fund.
Read More
UK regulatory approval for SCIB1 phase II advanced melanoma trial
The study is designed to assess whether the addition of SCIB1 treatment will result in an improvement in the tumour response rate.
Read More
Keytruda combo wins FDA approval for RCC
The approval is based on results of the KEYNOTE-426 study, in which Keytruda in combination with Inlyta was found to reduce the risk of death by nearly half compared to Sutent.
Read More
EU approves new dosing schedule for MSD’s Keytruda
The less frequent dosing gives both patients and oncologists more flexibility, helping to free up hospitals.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
